“revlimid” Archives

Entry Author Date Location
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B 01/03/19 National
Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups   07/27/18 National
With New Data, Karyopharm Says It Will Ask for Myeloma Approval 04/30/18 Boston
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others 09/07/17 New York
Celgene Narrows Its Relationship With Sutro, No Acquisition Coming 08/10/17 New York
Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More 07/29/16 National
ASCO Roundup: Checkpoints, Pushback Against Prices, CAR-T & More 06/02/15 National
East Coast Biotech Roundup: Vertex, Syndax, Build-to-Buy Deals & More 02/20/15 Boston
West Coast Biotech Roundup: NanoString, Sequenom/Agena, CIRM, & More 06/06/14 San Diego
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
Concert Pharma To Get $300M+ Per Drug in Celgene Pact 05/06/13 Boston
Celgene Puts $35M into VentiRx, Gets Option to Buy Cancer Drugmaker 10/03/12 Seattle
Celgene Pours $15M Into Acetylon, Takes “Observer” Role on Board 02/09/12 Boston
Onyx Drug Effective in New Myeloma Patients, Taking Aim at Millennium 12/12/11 San Francisco
Onyx Unveils Results for Myeloma Drug, Raising Stakes in Rivalry with Millennium 12/07/10 San Francisco
It’s True: Using More FDA ‘Wheels’ Under Cancer Drugs Can Speed Approval 09/13/10 San Francisco
Onyx Preps for Dash to FDA, After Myeloma Drug Helps Sickest of the Sick 07/26/10 San Francisco
The Top Five Biotech Innovations of the 2000s 12/15/09 Seattle
Millennium’s Velcade, As Time Wears On, Shows Durable Ability to Prolong Lives 12/08/08 Boston
Millennium CEO Dunsire Juggles Growing Pipeline, Works to Maintain Nimble Culture—as New Owner Takeda Makes the Company its Center for Cancer Drug Development 09/10/08 Boston
Page 1 of 1